Treatment and prevention of cancer using her3 antigen-binding molecules

Abstract

Methods for treating or preventing a cancer in a subject are disclosed, wherein the cancer comprises cells having a mutation resulting in increased expression of a ligand for HER3, wherein the method comprises administering a therapeutically or prophylactically effective amount of an antigen-binding molecule which is capable of binding to HER3 to the subject.

1 - 16 . (canceled) 
     
     
         17 . A method of treating a cancer in a subject, wherein the cancer comprises cells having a mutation resulting in increased expression of a ligand for HER3, wherein the method comprises administering a therapeutically or prophylactically effective amount of an antigen-binding molecule which is capable of binding to HER3 to the subject, and wherein the antigen-binding molecule binds to the region of HER3 shown in SEQ ID NO:16. 
     
     
         18 . The method according to  claim 17 , wherein binding of the antigen-binding molecule to HER3 comprises contact with one or more amino acid residues of the region of HER3 shown in SEQ ID NO:229. 
     
     
         19 . The method according to  claim 17 , wherein the ligand for HER3 comprises an amino acid sequence having at least 60% sequence identity to the EGF-like domain of an NRG. 
     
     
         20 . The method according to  claim 17 , wherein the mutation results in increased expression of the EGF-like domain of an NRG at the cell surface. 
     
     
         21 . The method according to  claim 17 , wherein the cancer comprises cells having an NRG gene fusion. 
     
     
         22 . The method according to  claim 21 , wherein the NRG gene fusion is selected from CLU-NRG1, CD74-NRG1, DOC4-NRG1, SLC3A2-NRG1, RBPMS-NRG1, WRN-NRG1, SDC4-NRG1, RAB2IL1-NRG1, VAMP2-NRG1, KIF13B-NRG1, THAP7-NRG1, SMAD4-NRG1, MDK-NRG1, TNC-NRG1, DIP2B-NRG1, MRPL13-NRG1, PARP8-NRG1, ROCK1-NRG1, DPYSL2-NRG1, ATP1B1-NRG1, CDH6-NRG1, APP-NRG1, AKAP13-NRG1, THBS1-NRG1, FOXA1-NRG1, PDE7A-NRG1, RAB3IL1-NRG1, CDK1-NRG1, BMPRIB-NRG1, TNFRSF10B-NRG1, MCPH1-NRG1 and SLC12A2-NRG2. 
     
     
         23 . The method according to  claim 21 , wherein the NRG gene fusion is selected from CLU-NRG1, CD74-NRG1, SLC3A2-NRG1 or VAMP2-NRG1. 
     
     
         24 . The method according to  claim 17 , wherein the cancer comprises cells expressing HER3. 
     
     
         25 . The method according to  claim 17 , wherein the cancer derives from the lung, breast, head, neck, kidney, ovary, pancreas, prostate, uterus, gallbladder, colon, rectum, bladder, soft tissue or nasopharynx. 
     
     
         26 . The method according to  claim 17 , wherein the cancer is selected from lung cancer, non-small cell lung cancer, lung adenocarcinoma, invasive mucinous lung adenocarcinoma, lung squamous cell carcinoma, breast cancer, breast carcinoma, breast invasive carcinoma, head and neck cancer, head and neck squamous cell carcinoma, renal cancer, renal clear cell carcinoma, ovarian cancer, ovarian serous cystadenocarcinoma, pancreatic cancer, pancreatic adenocarcinoma, pancreatic ductal adenocarcinoma, prostate cancer, prostate adenocarcinoma, endometrial cancer, uterine carcinosarcoma, gallbladder cancer, cholangiocarcinoma, colorectal cancer, bladder cancer, urothelial bladder cancer, sarcoma, soft tissue sarcoma, neuroendocrine tumor and neuroendocrine tumor of the nasopharynx. 
     
     
         27 . The method according to  claim 18 , wherein the cancer is selected from lung cancer, non-small cell lung cancer, lung adenocarcinoma, invasive mucinous lung adenocarcinoma and lung squamous cell carcinoma. 
     
     
         28 . The method according to  claim 17 , wherein the antigen-binding molecule comprises:
 a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:36; and   a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:83.   
     
     
         29 . The method according to  claim 17 , wherein the antigen-binding molecule comprises:
 a VH region incorporating the following framework regions (FRs):   HC-FR1 having the amino acid sequence of SEQ ID NO:53   HC-FR2 having the amino acid sequence of SEQ ID NO:59   HC-FR3 having the amino acid sequence of SEQ ID NO:66   HC-FR4 having the amino acid sequence of SEQ ID NO:71.   
     
     
         30 . The method according to  claim 17 , wherein the antigen-binding molecule comprises:
 a VL region incorporating the following framework regions (FRs):   LC-FR1 having the amino acid sequence of SEQ ID NO:104   LC-FR2 having the amino acid sequence of SEQ ID NO:110   LC-FR3 having the amino acid sequence of SEQ ID NO:120   LC-FR4 having the amino acid sequence of SEQ ID NO:125.   
     
     
         31 . The method according to  claim 17 , wherein the antigen-binding molecule comprises:
 a VH region comprising the amino acid sequence of SEQ ID NO:36; and   a VL region comprising the amino acid sequence of SEQ ID NO:83.   
     
     
         32 . The method according to  claim 17 , wherein the antigen-binding molecule comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:171. 
     
     
         33 . The method according to  claim 17 , wherein the antigen-binding molecule comprises a light chain comprising the amino acid sequence of SEQ ID NO:177.